Insulin- and obesity-related variables in early-stage breast cancer: Correlations and time course of prognostic associations

Journal of Clinical Oncology

Volumn 30, Issue 2, 2012, Pages 164-171

  Goodwin, Pamela J ^a   Ennis, Marguerite ^d   Pritchard, Kathleen I ^a   Trudeau, Maureen E ^a   Koo, Jarley ^b   Taylor, Sara K ^e   Hood, Nicky ^c  

^a UNIVERSITY OF TORONTO   (Canada)

^b ST MICHAEL'S HOSPITAL   (Canada)

^c MOUNT SINAI HOSPITAL   (Canada)

^d NONE

^e BRITISH COLUMBIA CANCER AGENCY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

C PEPTIDE; GLUCOSE; INSULIN; LEPTIN;

ADJUVANT CHEMOTHERAPY; ADULT; ARTICLE; BODY MASS; BREAST CANCER; CANCER MORTALITY; CANCER RECURRENCE; CANCER STAGING; CLINICAL ASSESSMENT TOOL; EARLY CANCER; FEMALE; HIP; HUMAN; INSULIN BLOOD LEVEL; MAJOR CLINICAL STUDY; OBESITY; OVERALL SURVIVAL; PEARSON SYNDROME; PRIORITY JOURNAL; PROGNOSIS; WAIST CIRCUMFERENCE;

AGED; AGED, 80 AND OVER; BODY MASS INDEX; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; INSULIN; LEPTIN; MIDDLE AGED; NEOPLASM STAGING; OBESITY; PROGNOSIS; RISK FACTORS;

EID: 84855604629     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.36.2723     Document Type: Article

References (28)

1. Protani M, Coory M, Martin JH: Effect of obesity on survival of women with breast cancer: Systematic review and meta-analysis. Breast Cancer Res Treat 123:627-635, 2010
2. Goodwin PJ, Ennis M, Pritchard KI, et al: Fasting insulin and outcome in early stage breast cancer: Results of a prospective cohort study. J Clin Oncol 20:42-51, 2002 (Pubitemid 34032594)
3. Pritchard KI, Shepherd L, Chapman JA, et al: A Randomized trial of tamoxifen versus combined tamoxifen and octreotide LAR therapy in the adjuvant treatment of early stage breast cancer in postmenopausal women: NCIC CTG MA. 14. J Clin Oncol 29:3869-3876, 2011
4. Pasanisi P, Berrino F, De Petris M, et al: Metabolic syndrome as a prognostic factor for breast cancer recurrences. Int J Cancer 119:236-238, 2006
5. Irwin ML, Duggan C, Wang CY, et al: Fasting C-peptide levels and death resulting from all causes and breast cancer: The Health, Eating, Activity, and Lifestyle Study. J Clin Oncol 29:47-53, 2011
6. Ewertz M, Jensen MB, Gunnarsdóttir KÁ, et al: Effect of obesity on prognosis after early-stage breast cancer. J Clin Oncol 29:25-31, 2011
7. Mulligan AM, O'Malley FP, Ennis M, et al: Insulin receptor is an independent predictor of a favorable outcome in early stage breast cancer. Breast Cancer Res Treat 106:39-47, 2007 (Pubitemid 47498088)
8. Law JH, Habibi G, Hu K, et al: Phosphorylated insulin-like growth factor-i/insulin receptor is present in all breast cancer subtypes and is related to poor survival. Cancer Res 68:10238-10246, 2008
9. Belfiore A: The role of insulin receptor isoforms and hybrid insulin/IGF-I receptors in human cancer. Curr Pharm Des 13:671-686, 2007
10. Frasca F, Pandini G, Scalia P, et al: Insulin receptor isoform A, a newly recognized, high-affinity insulin-like growth factor II receptor in fetal and cancer cells. Mol Cell Biol 19:3278-3288, 1999 (Pubitemid 29193789)
11. Goodwin PJ, Ennis M, Fantus IG, et al: Is leptin a mediator of adverse prognostic effects of obesity in breast cancer? J Clin Oncol 23:6037-6042, 2005
12. Chlebowski RT, Blackburn GL, Thomson CA, et al: Dietary fat reduction and breast cancer outcome: Interim efficacy results from the Women's Intervention Nutrition Study. J Natl Cancer Inst 98:1767-1776, 2006 (Pubitemid 46017928)
13. Sparano JA, Wang M, Martino S, et al: Obesity at diagnosis is associated with inferior outcomes in hormone receptor positive breast cancer. Cancer Res 70, 2010 (suppl 24; abstr nr S2-1)
14. Chen X, Wei L, Zheng W, et al: Obesity and weight change in relation to breast cancer survival. Breast Cancer Res Treat 122:823-833, 2010
15. de Azambuja E, McCaskill-Stevens W, Francis P, et al: The effect of body mass index on overall and disease-free survival in node-positive breast cancer patients treated with docetaxel and doxorubicin-containing adjuvant chemotherapy: The experience of the BIG 02-98 trial. Breast Cancer Res Treat 119:145-153, 2010
16. Majed B, Moreau t, Senouci K, et al: Is obesity an independent prognosis factor in woman breast cancer? Breast Cancer Res Treat 111:329-342, 2008
17. Vitolins M, Kimmick GG, Case LD: BMI influences prognosis following surgery and adjuvant chemotherapy for lymph node positive breast cancer. Breast J 14:357-365, 2008
18. Goodwin PJ, Ennis M, Pritchard KI, et al: Insulin-like growth factor binding proteins 1 and 3 and breast cancer outcomes. Breast Cancer Res Treat 74:65-76, 2002 (Pubitemid 34734598)
19. Wallace TM, Matthews DR: The assessment of insulin resistance in man. Diabet Med 19:527-534, 2002 (Pubitemid 35300672)
20. Bonora E, Targher G, Alberiche M, et al: Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: Studies in subjects with various degrees of glucose tolerance and insulin sensitivity. Diabetes Care 23:57-63, 2000 (Pubitemid 30022895)
21. Grambsch PM, Therneau TM: Proportional hazards tests and diagnostics based on weighted residuals. Biometrika 81:515-526, 1994
22. Therneau TM, Grambsch PM: Testing proportional hazards, in Dietz K, Gail M, Krickeberg K, et al (eds): Modeling Survival Data: Extending the Cox Model. New York, NY, Springer-Verlag, 2000, pp 127-148
23. Anderson WF, Chen BE, Jatoi I, et al: Effects of estrogen receptor expression and histopathology on annual hazard rates of death from breast cancer. Breast Cancer Res Treat 100:121-126, 2006
24. Suissa S, Pollak M, Spitzer WO, et al: Body size and breast cancer prognosis: A statistical explanation of the discrepancies. Cancer Res 49:3113-3116, 1989 (Pubitemid 19148654)
25. Muti P, Quattrin T, Grant BJ, et al: Fasting glucose is a risk factor for breast cancer: A prospective study. Cancer Epidemiol Biomarkers Prev 11: 1361-1368, 2002 (Pubitemid 35340370)
26. Peairs KS, Barone BB, Snyder CF, et al: Diabetes mellitus and breast cancer outcomes: A systematic review and meta-analysis. J Clin Oncol 29:40-46, 2011
27. Knowler WC, Barrett-Connor E, Fowler SE, et al: Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346:393-403, 2002 (Pubitemid 34437694)
28. Goodwin PJ, Stambolic V, Lemieux J, et al: Evaluation of metformin in early breast cancer: A modification of the traditional paradigm for clinical testing of anti-cancer agents. Breast Cancer Res Treat 126:215-220, 2011